<DOC>
	<DOCNO>NCT00244751</DOCNO>
	<brief_summary>The purpose study examine safety effectiveness GI262570 compare placebo ( pill look exactly like GI262570 contains active medicine ) improve specific test indicate degree liver fibrosis ( scar ) . Subjects enrol study must prior treatment interferon ( either pegylated standard interferon ) plus ribavirin least 12 week treat hepatitis C , either fail clear virus n't tolerate treatment .</brief_summary>
	<brief_title>Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Inclusion criterion : A subject eligible inclusion study follow criterion apply : Age 40 70 year , inclusive . Documented positive serology HCV antibody second generation high assay . Serum HCV RNA positive HCV viral Genotype 1 prescreening visit . Ishak fibrosis score 2 , 3 4 . Failure achieve sustain virologic response ( SVR ) previous interferon ( standard pegylated ) ribavirin treatment administer minimum dose 3mU three time weekly equivalent , least 12 week . Reasons failure may include failure respond treatment intolerability optimal treatment . Prior treatment interferon/ribavirin must discontinue least 11 month prior biopsy date . Male female ; female eligible enter participate study : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ) ; , 2. childbearing potential , negative serum pregnancy test screen , agree one following : Complete abstinence intercourse 2 week prior administration study drug , throughout study , time interval completion premature discontinuation study account elimination investigational drug , ( minimum 5 halflives longer pharmacodynamic profile investigational drug warrant long time period ) ; , Female sterilization ; , Has male partner sterilize ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combine progestogen ) , must stable 3 month prior study entry ; , Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Any method publish data show low expected failure rate method le 1 % per year ; , Barrier method use combination acceptable method . Availability willingness subject provide write informed consent . Exclusion criterion : A subject eligible inclusion study follow criterion apply : History ascites , variceal hemorrhage , hepatic encephalopathy , spontaneous bacterial peritonitis sign hepatic decompensation . Current historical evidence suggestive ischemic heart disease cardiovascular disease investigator 's opinion may adversely impact safety subject conduct study . Evidence suggestive cardiovascular disease may come number source , include clinical history , physical exam , electrocardiogram , laboratory testing , radiographic procedure . New York Heart Association ( NYHA ) Functional Class 1 , 2 , 3 , 4 cardiac status Coinfection HBV HIV . Liver histology consistent coexisting cause chronic liver disease . Documented evidence hepatic mass lesion suspicious hepatocellular carcinoma . Alphafetoprotein &gt; 200ng/mL prescreening . Inadequate hematologic function define follow : Hemoglobin ( &lt; 12.5 g/dL men ) ( &lt; 12.0 g/dL woman ) Absolute Neutrophil Count ( ANC ) ( &lt; 1.0 x 10^9/L ) Platelets ( &lt; 130X/10^9/L ) Inadequate renal function define : Serum creatinine ( &gt; 1.5mg/dL ( ≥130mmol/L ) ) Calculated creatinine clearance calculate Cockcroft Gault ( &lt; 60mL/min ) Serum ALT level ≥5 x ULN . Albumin &lt; 3.2g/dL . Total bilirubin &gt; 1.2 x ULN . Prothrombin time &gt; 15 second International normalize ratio ( INR ) &gt; 1.3 . Organ , stem cell , bone marrow transplant . Serious concurrent medical illness investigator 's opinion might interfere therapy . This include significant systemic illness ( liver disease ) chronic pancreatitis . Active systemic autoimmune disorder . A preexisting condition interfere normal gastrointestinal anatomy motility , and/or renal function could interfere absorption , metabolism , and/or excretion study drug . Other medical condition , investigator 's opinion , might interfere compliance therapy , participation study interpretation result . Pregnancy ( lactation ) , subject capable bearing child , inability/unwillingness practice adequate contraception . Females childbearing potential ( postpuberty ) unwilling unable pregnancy test study visit . Therapy systemic cytotoxic agent , immunomodulators , immunosuppressive therapy require use 5mg prednisone ( equivalent ) per day . Therapy systemic antiviral agent ( exception prophylaxis treatment influenza chronic HSV ) within past 30 day . Concurrent participation another clinical trial subject expose another investigational noninvestigational drug device within 30 day screen visit . Current therapy anticipate need therapy hypoglycemic drug ( e.g. , insulin , sulfonylurea metformin ) . Known hypersensitivity GI262570 , component GI262570 soft gelatin capsule , dispersion tablet sodium salt tablet PPARg agonists . A history hepatotoxicity TZDs and/or history severe edema medically serious fluidrelated event associate use TZDs . Use PPAR agonist ( e.g. , rosiglitazone , pioglitazone ) within 1 year start dosing . Active alcohol abuse within past 1 year . Use illegal drug past 1 year . 30a . Macular edema history macular edema .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatitis C liver fibrosis</keyword>
</DOC>